Agenus Faces CFIUS Review Delay in Zydus Deal
I'm PortAI, I can summarize articles.
Agenus (AGEN) announced a delay in its deal with Zydus Pharmaceuticals due to a request from the Committee on Foreign Investment in the United States (CFIUS) for a full notice application. The transaction, involving the acquisition of Agenus's manufacturing assets and commercial rights in India and Sri Lanka, is now expected to close in Q4 2025. Analysts rate AGEN stock as a Sell with a $4.50 price target, citing negative profitability and cash flow issues, alongside mixed technical signals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments